Payment overview · 2025
General Payments
$1,067.20
57 reported records · 20 companies
Healthcare provider profile · identity verified
Daniel C Woods, MD
Allopathic & Osteopathic Physicians|Family Medicine · SAVANNA, IL · NPI 1942276159
Verified facts
What the public records show
CMS Open Payments records show Daniel C Woods, MD received $1,067.20 in general payments during 2025 across 57 reported records.
Amgen Inc. accounted for 13.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Jardiance, Mounjaro, Paxlovid, Rexulti, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 463 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 272 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 391 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 298 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 272 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Mounjaro by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 391 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $139.55 | 13.1% | 11 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $115.57 | 10.8% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $115.19 | 10.8% | 5 | 2025 |
| Catalyst OrthoScience | Unresolved — no canonical attribution shown | $84.11 | 7.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $83.07 | 7.8% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $66.48 | 6.2% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $60.38 | 5.7% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $59.26 | 5.5% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $54.48 | 5.1% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $53.99 | 5.1% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $35.74 | 3.4% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $34.10 | 3.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.19 | 2.9% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.72 | 2.5% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $22.31 | 2.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.92 | 1.8% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $18.19 | 1.7% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $16.48 | 1.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.85 | 1.5% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.62 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,067.20 | 57 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $131.85 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $111.61 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $111.61 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $71.83 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $69.69 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $66.79 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $60.38 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $59.26 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $54.48 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $52.60 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $46.73 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $38.16 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $35.74 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $34.10 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $34.10 | 2 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $34.10 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $31.19 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $31.19 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $27.94 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $26.72 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| PROQUAD Normalized: proquad |
Biological | Merck Sharp & Dohme LLC | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $16.48 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $15.91 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 33 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 391 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 463 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 272 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 17 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 63 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
32 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
463 | 56 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
272 | 33 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
391 | 55 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
33 | 33 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
63 | 47 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
298 | 54 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
272 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
74 | 74 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
391 | 55 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 957 | 225 |
| Furosemide | Furosemide | 619 | 123 |
| Carvedilol | Carvedilol | 600 | 134 |
| Gabapentin | Gabapentin | 552 | 99 |
| Pantoprazole Sodium | Pantoprazole Sodium | 517 | 126 |
| Levothyroxine Sodium | Levothyroxine Sodium | 499 | 103 |
| Metformin Hcl | Metformin Hcl | 469 | 99 |
| Farxiga | Dapagliflozin Propanediol | 463 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 433 | 113 |
| Lisinopril | Lisinopril | 430 | 104 |
| Potassium Chloride | Potassium Chloride | 425 | 77 |
| Metoprolol Tartrate | Metoprolol Tartrate | 395 | 73 |
| Eliquis | Apixaban | 391 | 55 |
| Spironolactone | Spironolactone | 372 | 77 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 354 | 76 |
| Omeprazole | Omeprazole | 352 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 314 | 90 |
| Tamsulosin Hcl | Tamsulosin Hcl | 303 | 68 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 298 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 294 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 294 | 79 |
| Tramadol Hcl | Tramadol Hcl | 294 | 61 |
| Prednisone | Prednisone | 286 | 154 |
| Mirtazapine | Mirtazapine | 273 | 50 |
| Quetiapine Fumarate | Quetiapine Fumarate | 273 | 32 |
| Jardiance | Empagliflozin | 272 | 33 |
| Sertraline Hcl | Sertraline Hcl | 268 | 37 |
| Xarelto | Rivaroxaban | 237 | 36 |
| Losartan Potassium | Losartan Potassium | 234 | 55 |
| Duloxetine Hcl | Duloxetine Hcl | 229 | 42 |
| Donepezil Hcl | Donepezil Hcl | 226 | 27 |
| Finasteride | Finasteride | 226 | 47 |
| Rybelsus | Semaglutide | 214 | 37 |
| Lorazepam | Lorazepam | 208 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 207 | 46 |
| Montelukast Sodium | Montelukast Sodium | 194 | 46 |
| Simvastatin | Simvastatin | 192 | 43 |
| Trazodone Hcl | Trazodone Hcl | 190 | 42 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 184 | 41 |
| Allopurinol | Allopurinol | 182 | 38 |
| Celecoxib | Celecoxib | 178 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 170 | 54 |
| Bumetanide | Bumetanide | 165 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 162 | 41 |
| Fentanyl | Fentanyl | 159 | 17 |
| Memantine Hcl | Memantine Hcl | 155 | 17 |
| Januvia | Sitagliptin Phosphate | 152 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 151 | 29 |
| Clonazepam | Clonazepam | 149 | 32 |
| Risperidone | Risperidone | 142 | 14 |
| Warfarin Sodium | Warfarin Sodium | 141 | suppressed |
| Levetiracetam | Levetiracetam | 137 | 16 |
| Fenofibrate | Fenofibrate | 135 | 36 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 126 | 22 |
| Myrbetriq | Mirabegron | 125 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 119 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 118 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 117 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 117 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 116 | 15 |
| Levofloxacin | Levofloxacin | 111 | 68 |
| Meloxicam | Meloxicam | 107 | 31 |
| Ozempic | Semaglutide | 103 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 101 | 60 |
| Paroxetine Hcl | Paroxetine Hcl | 99 | 19 |
| Cholestyramine | Cholestyramine (With Sugar) | 98 | 16 |
| Morphine Sulfate | Morphine Sulfate | 96 | 36 |
| Pregabalin | Pregabalin | 93 | 21 |
| Alprazolam | Alprazolam | 91 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 89 | 16 |
| Fluconazole | Fluconazole | 89 | 49 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 87 | 20 |
| Latanoprost | Latanoprost | 87 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 86 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 85 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 84 | 60 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 84 | 20 |
| Repatha Sureclick | Evolocumab | 84 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 82 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 79 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 21 |
| Metoclopramide Hcl | Metoclopramide Hcl | 77 | 13 |
| Azithromycin | Azithromycin | 76 | 65 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 76 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 75 | 13 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 74 | 74 |
| Morphine Sulfate Er | Morphine Sulfate | 73 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 73 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 73 | 14 |
| Famotidine | Famotidine | 70 | 16 |
| Lovastatin | Lovastatin | 70 | 21 |
| Aripiprazole | Aripiprazole | 69 | suppressed |
| Cefdinir | Cefdinir | 68 | 47 |
| Mometasone Furoate | Mometasone Furoate | 68 | 31 |
| Bupropion Hcl | Bupropion Hcl | 67 | suppressed |
| Primidone | Primidone | 67 | suppressed |
| Cephalexin | Cephalexin | 66 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 66 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 65 | 14 |
| Atenolol | Atenolol | 64 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 64 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 63 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 63 | 47 |
| Bupropion Xl | Bupropion Hcl | 61 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 61 | suppressed |
| Ezetimibe | Ezetimibe | 60 | 17 |
| Nifedipine Er | Nifedipine | 60 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 59 | 17 |
| Olanzapine | Olanzapine | 57 | 11 |
| Digoxin | Digoxin | 56 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 55 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 53 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 51 | 22 |
| Amiodarone Hcl | Amiodarone Hcl | 50 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 49 | suppressed |
| Lactulose | Lactulose | 49 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 49 | 13 |
| Buspirone Hcl | Buspirone Hcl | 48 | 11 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 48 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 48 | 18 |
| Metformin Hcl Er | Metformin Hcl | 47 | 15 |
| Mounjaro | Tirzepatide | 47 | suppressed |
| Premarin | Estrogens, Conjugated | 46 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 43 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 37 | 14 |
| Enalapril Maleate | Enalapril Maleate | 37 | 13 |
| Nystatin | Nystatin | 37 | 19 |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | suppressed |
| Ketoconazole | Ketoconazole | 36 | 22 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 35 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 34 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 33 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 13 |
| Glipizide | Glipizide | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | 12 |
| Hydromorphone Hcl | Hydromorphone Hcl | 32 | suppressed |
| Linzess | Linaclotide | 32 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 30 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Rexulti | Brexpiprazole | 30 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Admelog Solostar | Insulin Lispro | 29 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 29 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 29 | 12 |
| Spiriva Respimat | Tiotropium Bromide | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Cilostazol | Cilostazol | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 27 | suppressed |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | suppressed |
| Sotalol | Sotalol Hcl | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Dexamethasone | Dexamethasone | 24 | 22 |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 21 |
| Sucralfate | Sucralfate | 24 | suppressed |
| Mupirocin | Mupirocin | 23 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Amantadine | Amantadine Hcl | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 19 |
| Budesonide | Budesonide | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Lorazepam Intensol | Lorazepam | 22 | 17 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 22 | 22 |
| Baclofen | Baclofen | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 20 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 20 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 11 |
| Hydrocortisone | Hydrocortisone | 19 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 19 | suppressed |
| Novolog | Insulin Aspart | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Timolol Maleate | Timolol Maleate | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Insulin Lispro | Insulin Lispro | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Ssd | Silver Sulfadiazine | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Mesalamine | Mesalamine | 15 | suppressed |
| Scopolamine | Scopolamine | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Rytary | Carbidopa/Levodopa | 14 | suppressed |
| Xtampza Er | Oxycodone Myristate | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 11 |
| Atropine Sulfate | Atropine Sulfate | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Sodium Polystyrene Sulfonate | Sodium Polystyrene Sulfonate | 13 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Sotalol Af | Sotalol Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,067.20 · 57 records | Amgen Inc. | AREXVY, ARISTADA, AUSTEDO XR, BEXSERO, CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, GARDASIL 9, INGREZZA, JARDIANCE, Korlym, LYBALVI, MOUNJARO, NURTEC ODT, OTEZLA, PAXLOVID, PROQUAD, QULIPTA, REPATHA, REXULTI, SHINGRIX, UBRELVY, VAXNEUVANCE, VOQUEZNA, ZEPBOUND, ZORYVE | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error